. Clinical trial design of CREAD: a randomized, double-blind, placebo-controlled, parallel-group Phase-3 study to evaluate crenezumab treatment in patients with prodromal-to-mild Alzheimer’s disease. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 12.7 (2016): P609.


Please login to recommend the paper.


No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:


  1. Crenezumab